Zobrazeno 1 - 6
of 6
pro vyhledávání: '"Geck Do MK"'
Autor:
Pilié PG; Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas., Giuliani V; TRACTION (Translational Research to Advance Therapeutics and Innovation in Oncology), The University of Texas MD Anderson Cancer Center, Houston, Texas., Wang WL; Department of Pathology, The University of Texas MD Anderson Cancer Center, Houston, Texas., McGrail DJ; Center for Immunotherapy and Precision Immuno-Oncology, Cleveland Clinic, Cleveland, Ohio., Bristow CA; TRACTION (Translational Research to Advance Therapeutics and Innovation in Oncology), The University of Texas MD Anderson Cancer Center, Houston, Texas., Ngoi NYL; Department of Investigational Cancer Therapeutics (Phase I Program), Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas., Kyewalabye K; Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas., Wani KM; Department of Pathology, The University of Texas MD Anderson Cancer Center, Houston, Texas., Le H; Department of Investigational Cancer Therapeutics (Phase I Program), Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas., Campbell E; Department of Investigational Cancer Therapeutics (Phase I Program), Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas., Sanchez NS; Institute for Personalized Cancer Therapy, The University of Texas MD Anderson Cancer Center, Houston, Texas., Yang D; Institute for Personalized Cancer Therapy, The University of Texas MD Anderson Cancer Center, Houston, Texas., Gheeya JS; The University of Texas Health Science Center at Houston, Houston, Texas., Goswamy RV; The University of Texas Health Science Center at Houston, Houston, Texas., Holla V; Institute for Personalized Cancer Therapy, The University of Texas MD Anderson Cancer Center, Houston, Texas., Shaw KR; Institute for Personalized Cancer Therapy, The University of Texas MD Anderson Cancer Center, Houston, Texas., Meric-Bernstam F; Department of Investigational Cancer Therapeutics (Phase I Program), Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas.; Institute for Personalized Cancer Therapy, The University of Texas MD Anderson Cancer Center, Houston, Texas., Liu CY; TRACTION (Translational Research to Advance Therapeutics and Innovation in Oncology), The University of Texas MD Anderson Cancer Center, Houston, Texas., Ma X; TRACTION (Translational Research to Advance Therapeutics and Innovation in Oncology), The University of Texas MD Anderson Cancer Center, Houston, Texas., Feng N; TRACTION (Translational Research to Advance Therapeutics and Innovation in Oncology), The University of Texas MD Anderson Cancer Center, Houston, Texas., Machado AA; TRACTION (Translational Research to Advance Therapeutics and Innovation in Oncology), The University of Texas MD Anderson Cancer Center, Houston, Texas., Bardenhagen JP; Institute for Applied Cancer Science, The University of Texas MD Anderson Cancer Center, Houston, Texas., Vellano CP; TRACTION (Translational Research to Advance Therapeutics and Innovation in Oncology), The University of Texas MD Anderson Cancer Center, Houston, Texas., Marszalek JR; TRACTION (Translational Research to Advance Therapeutics and Innovation in Oncology), The University of Texas MD Anderson Cancer Center, Houston, Texas., Rajendra E; Artios Pharma, the Glenn Berge Building, Babraham Research Campus, Cambridge, United Kingdom., Piscitello D; Artios Pharma, the Glenn Berge Building, Babraham Research Campus, Cambridge, United Kingdom., Johnson TI; Artios Pharma, the Glenn Berge Building, Babraham Research Campus, Cambridge, United Kingdom., Likhatcheva M; Artios Pharma, the Glenn Berge Building, Babraham Research Campus, Cambridge, United Kingdom., Elinati E; Artios Pharma, the Glenn Berge Building, Babraham Research Campus, Cambridge, United Kingdom., Majithiya J; Artios Pharma, the Glenn Berge Building, Babraham Research Campus, Cambridge, United Kingdom., Neves J; Artios Pharma, the Glenn Berge Building, Babraham Research Campus, Cambridge, United Kingdom., Grinkevich V; Artios Pharma, the Glenn Berge Building, Babraham Research Campus, Cambridge, United Kingdom., Ranzani M; Artios Pharma, the Glenn Berge Building, Babraham Research Campus, Cambridge, United Kingdom., Luzarraga MR; Artios Pharma, the Glenn Berge Building, Babraham Research Campus, Cambridge, United Kingdom., Boursier M; Artios Pharma, the Glenn Berge Building, Babraham Research Campus, Cambridge, United Kingdom., Armstrong L; Artios Pharma, the Glenn Berge Building, Babraham Research Campus, Cambridge, United Kingdom., Geo L; Artios Pharma, the Glenn Berge Building, Babraham Research Campus, Cambridge, United Kingdom., Lillo G; Artios Pharma, the Glenn Berge Building, Babraham Research Campus, Cambridge, United Kingdom., Tse WY; Artios Pharma, the Glenn Berge Building, Babraham Research Campus, Cambridge, United Kingdom., Lazar AJ; Department of Pathology, The University of Texas MD Anderson Cancer Center, Houston, Texas.; Department of Genomic Medicine, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas., Kopetz SE; Department of Gastrointestinal Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas., Geck Do MK; Institute for Applied Cancer Science, The University of Texas MD Anderson Cancer Center, Houston, Texas., Lively S; ChemPartner Corporation, San Francisco, California., Johnson MG; ChemPartner Corporation, San Francisco, California., Robinson HMR; Artios Pharma, the Glenn Berge Building, Babraham Research Campus, Cambridge, United Kingdom., Smith GCM; Artios Pharma, the Glenn Berge Building, Babraham Research Campus, Cambridge, United Kingdom., Carroll CL; Institute for Applied Cancer Science, The University of Texas MD Anderson Cancer Center, Houston, Texas., Di Francesco ME; Institute for Applied Cancer Science, The University of Texas MD Anderson Cancer Center, Houston, Texas., Jones P; Institute for Applied Cancer Science, The University of Texas MD Anderson Cancer Center, Houston, Texas., Heffernan TP; TRACTION (Translational Research to Advance Therapeutics and Innovation in Oncology), The University of Texas MD Anderson Cancer Center, Houston, Texas., Yap TA; Department of Investigational Cancer Therapeutics (Phase I Program), Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas.; Institute for Personalized Cancer Therapy, The University of Texas MD Anderson Cancer Center, Houston, Texas.; Institute for Applied Cancer Science, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Publikováno v:
Clinical cancer research : an official journal of the American Association for Cancer Research [Clin Cancer Res] 2024 May 15; Vol. 30 (10), pp. 2121-2139.
Autor:
Giuliani V; Traction, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. VGiuliani@mdanderson.org., Miller MA; Traction, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Liu CY; Traction, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Hartono SR; Department of Molecular and Cellular Biology and Genome Center, University of California, Davis, CA, USA., Class CA; Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.; Department of Pharmaceutical Sciences, Butler University, Indianapolis, IN, USA., Bristow CA; Traction, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Suzuki E; Traction, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Sanz LA; Department of Molecular and Cellular Biology and Genome Center, University of California, Davis, CA, USA., Gao G; Traction, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Gay JP; Traction, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Feng N; Traction, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Rose JL; Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Tomihara H; Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.; Department of Surgery, Kindai University Nara Hospital, Nara, JP, USA., Daniele JR; Traction, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Peoples MD; Traction, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Bardenhagen JP; Institute for Applied Cancer Science, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Geck Do MK; Institute for Applied Cancer Science, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Chang QE; ORBIT, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Vangamudi B; Traction, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.; Exo Therapeutics, Cambridge, MA, USA., Vellano C; Traction, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Ying H; Department of Cellular and Molecular Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Deem AK; Traction, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Do KA; Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Genovese G; Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.; Department of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Marszalek JR; Traction, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Kovacs JJ; Traction, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Kim M; Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Fleming JB; Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.; Division of Gastrointestinal Oncology, H. Lee Moffitt Cancer Center, Tampa, FL, USA., Guccione E; Department of Oncological Sciences and Pharmacological Sciences at Icahn School of Medicine at Mount Sinai, New York, NY, USA., Viale A; Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Maitra A; Sheikh Ahmed Bin Zayed Al Nahyan Center for Pancreatic Cancer Research, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Emilia Di Francesco M; Institute for Applied Cancer Science, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Yap TA; Department of Investigational Cancer Therapeutics (Phase I Program), The University of Texas MD Anderson Cancer Center, Houston, Texas, USA., Jones P; Institute for Applied Cancer Science, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Draetta G; Traction, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.; Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.; Institute for Applied Cancer Science, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Carugo A; Traction, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Chedin F; Department of Molecular and Cellular Biology and Genome Center, University of California, Davis, CA, USA., Heffernan TP; Traction, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. TPHeffernan@mdanderson.org.
Publikováno v:
Nature communications [Nat Commun] 2021 Jul 30; Vol. 12 (1), pp. 4626. Date of Electronic Publication: 2021 Jul 30.
Autor:
Zhan Y; Institute for Applied Cancer Science, The University of Texas MD Anderson Cancer Center, Houston, TX 77230 USA., Kost-Alimova M; Institute for Applied Cancer Science, The University of Texas MD Anderson Cancer Center, Houston, TX 77230 USA., Shi X; Institute for Applied Cancer Science, The University of Texas MD Anderson Cancer Center, Houston, TX 77230 USA., Leo E; Institute for Applied Cancer Science, The University of Texas MD Anderson Cancer Center, Houston, TX 77230 USA., Bardenhagen JP; Institute for Applied Cancer Science, The University of Texas MD Anderson Cancer Center, Houston, TX 77230 USA., Shepard HE; Institute for Applied Cancer Science, The University of Texas MD Anderson Cancer Center, Houston, TX 77230 USA., Appikonda S; Department of Epigenetics and Molecular Carcinogenesis, The University of Texas MD Anderson Cancer Center, Houston, TX 77230 USA., Vangamudi B; Institute for Applied Cancer Science, The University of Texas MD Anderson Cancer Center, Houston, TX 77230 USA., Zhao S; Institute for Applied Cancer Science, The University of Texas MD Anderson Cancer Center, Houston, TX 77230 USA., Tieu TN; Institute for Applied Cancer Science, The University of Texas MD Anderson Cancer Center, Houston, TX 77230 USA., Jiang S; Department of Epigenetics and Molecular Carcinogenesis, The University of Texas MD Anderson Cancer Center, Houston, TX 77230 USA., Heffernan TP; Institute for Applied Cancer Science, The University of Texas MD Anderson Cancer Center, Houston, TX 77230 USA., Marszalek JR; Institute for Applied Cancer Science, The University of Texas MD Anderson Cancer Center, Houston, TX 77230 USA., Toniatti C; Institute for Applied Cancer Science, The University of Texas MD Anderson Cancer Center, Houston, TX 77230 USA., Draetta G; Institute for Applied Cancer Science, The University of Texas MD Anderson Cancer Center, Houston, TX 77230 USA., Tyler J; Department of Epigenetics and Molecular Carcinogenesis, The University of Texas MD Anderson Cancer Center, Houston, TX 77230 USA., Barton M; Department of Epigenetics and Molecular Carcinogenesis, The University of Texas MD Anderson Cancer Center, Houston, TX 77230 USA., Jones P; Institute for Applied Cancer Science, The University of Texas MD Anderson Cancer Center, Houston, TX 77230 USA., Palmer WS; Institute for Applied Cancer Science, The University of Texas MD Anderson Cancer Center, Houston, TX 77230 USA., Geck Do MK; Institute for Applied Cancer Science, The University of Texas MD Anderson Cancer Center, Houston, TX 77230 USA., Andersen JN; Institute for Applied Cancer Science, The University of Texas MD Anderson Cancer Center, Houston, TX 77230 USA.; XTuit Pharmaceuticals, 700 Main Street, Cambridge, MA 02139 USA.
Publikováno v:
Epigenetics & chromatin [Epigenetics Chromatin] 2015 Sep 21; Vol. 8, pp. 37. Date of Electronic Publication: 2015 Sep 21 (Print Publication: 2015).
Autor:
Poncet-Montange G; Institute for Applied Cancer Science, The University of Texas MD Anderson Cancer Center, Unit 1954, 1515 Holcombe Blvd, Houston, TX 77030, U.S.A., Zhan Y; Institute for Applied Cancer Science, The University of Texas MD Anderson Cancer Center, Unit 1954, 1515 Holcombe Blvd, Houston, TX 77030, U.S.A., Bardenhagen JP; Institute for Applied Cancer Science, The University of Texas MD Anderson Cancer Center, Unit 1954, 1515 Holcombe Blvd, Houston, TX 77030, U.S.A., Petrocchi A; Institute for Applied Cancer Science, The University of Texas MD Anderson Cancer Center, Unit 1954, 1515 Holcombe Blvd, Houston, TX 77030, U.S.A., Leo E; Institute for Applied Cancer Science, The University of Texas MD Anderson Cancer Center, Unit 1954, 1515 Holcombe Blvd, Houston, TX 77030, U.S.A., Shi X; Institute for Applied Cancer Science, The University of Texas MD Anderson Cancer Center, Unit 1954, 1515 Holcombe Blvd, Houston, TX 77030, U.S.A., Lee GR 4th; †Department of Biochemistry and Molecular Biology and Center for Biomolecular Structure and Function, The University of Texas MD Anderson Cancer Center, Unit 1000, 1515 Holcombe Boulevard, Houston TX 77030, U.S.A., Leonard PG; Institute for Applied Cancer Science, The University of Texas MD Anderson Cancer Center, Unit 1954, 1515 Holcombe Blvd, Houston, TX 77030, U.S.A., Geck Do MK; Institute for Applied Cancer Science, The University of Texas MD Anderson Cancer Center, Unit 1954, 1515 Holcombe Blvd, Houston, TX 77030, U.S.A., Cardozo MG; Institute for Applied Cancer Science, The University of Texas MD Anderson Cancer Center, Unit 1954, 1515 Holcombe Blvd, Houston, TX 77030, U.S.A., Andersen JN; Institute for Applied Cancer Science, The University of Texas MD Anderson Cancer Center, Unit 1954, 1515 Holcombe Blvd, Houston, TX 77030, U.S.A., Palmer WS; Institute for Applied Cancer Science, The University of Texas MD Anderson Cancer Center, Unit 1954, 1515 Holcombe Blvd, Houston, TX 77030, U.S.A., Jones P; Institute for Applied Cancer Science, The University of Texas MD Anderson Cancer Center, Unit 1954, 1515 Holcombe Blvd, Houston, TX 77030, U.S.A., Ladbury JE; †Department of Biochemistry and Molecular Biology and Center for Biomolecular Structure and Function, The University of Texas MD Anderson Cancer Center, Unit 1000, 1515 Holcombe Boulevard, Houston TX 77030, U.S.A.
Publikováno v:
The Biochemical journal [Biochem J] 2015 Mar 01; Vol. 466 (2), pp. 337-46.
Autor:
Thomas AA; Array BioPharma, 3200 Walnut Street, Boulder, Colorado 80301, United States., Hunt KW, Newhouse B, Watts RJ, Liu X, Vigers G, Smith D, Rhodes SP, Brown KD, Otten JN, Burkard M, Cox AA, Geck Do MK, Dutcher D, Rana S, DeLisle RK, Regal K, Wright AD, Groneberg R, Liao J, Scearce-Levie K, Siu M, Purkey HE, Lyssikatos JP
Publikováno v:
Journal of medicinal chemistry [J Med Chem] 2014 Dec 11; Vol. 57 (23), pp. 10112-29. Date of Electronic Publication: 2014 Nov 26.
Autor:
Hunt KW; Array BioPharma, 3200 Walnut Street, Boulder, CO 80301, USA. hunt@arraybiopharma.com, Cook AW, Watts RJ, Clark CT, Vigers G, Smith D, Metcalf AT, Gunawardana IW, Burkard M, Cox AA, Geck Do MK, Dutcher D, Thomas AA, Rana S, Kallan NC, DeLisle RK, Rizzi JP, Regal K, Sammond D, Groneberg R, Siu M, Purkey H, Lyssikatos JP, Marlow A, Liu X, Tang TP
Publikováno v:
Journal of medicinal chemistry [J Med Chem] 2013 Apr 25; Vol. 56 (8), pp. 3379-403. Date of Electronic Publication: 2013 Apr 16.